Autopsy report · NCT04865419
Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies
Cause of deathSafety
“Trial terminated based on benefit-risk profile assessment”
Life of this trial
- Registered 2 months before it started.
- Ran for about 2 years 2 months before it stopped.
- 46 participants enrolled.
- Results were posted on the registry 1 year 10 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- AstraZeneca
- Sponsor type
- Industry
- Conditions
- Haematological Malignancies
- Interventions
- AZD0466; Voriconazole
- Participants
- 46
- Sites
- 15
- Countries
- Australia, France, Germany, Italy, South Korea, United States
Trials that died the same way
- A Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients (MK-5592-105)
“Study terminated due to an unfavorable risk-benefit analysis” - A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
“The benefit-risk profile no longer supports continuing the study” - Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine
“Termination of the study was made after a full review of program data and assessment of the current risk-benefit profile.” - A Study of LY3463251 in Healthy Participants
“Trial was terminated due to an insufficient benefit/tolerability ratio” - A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia
“Trial terminated early per business decision”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.